Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →At the heart of the deal is Engage's Tethosome platform, tech that is designed to address current limitations in DNA delivery by improving potency,…
Eli Lilly maintains M&A streak with $202m Engage Bio buyout. The platform combines a lipid nanoparticle (LNP)-delivered DNA payload with an mRNA-encoded…
Lilly acquires preclinical non-viral DNA delivery platform from Engage Biologics for up to $202 million, adding to a genetic medicines build-out that already…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Eli Lilly acquired preclinical-stage Engage Biologics for up to $202 million, including an undisclosed upfront and development milestone payments. Engage's Tethosome platform uses lipid nanoparticles to deliver a DNA transgene vector and an mRNA-encoded DNA-binding protein for sustained episomal expression, with preclinical focus on liver targets including hemophilia A and hepatocellular carcinoma.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Engage Biologics, Inc. (this deal) | 2026 | $202M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2026 deals · Eli Lilly and Company deals · Hematology deals